Mycoplasma pneumoniae is a common cause of a wide range of upper and lower respiratory tract infections, especially in children and in young adults. Routine laboratory diagnosis of M. pneumoniae infection is based mainly on serology and, to a lesser extent, on cultivation. The complement fixation test is widely used for M. pneumoniae antibody detection but lacks specificity because of its crossreactivity with similar antigens, and it is poorly sensitive, especially with specimens from young children (8, 10) . Enzyme-linked immunosorbent assay (3, 7, 15) and microparticle agglutination (5) have been reported to be both more specific and more sensitive for antibody detection, but they usually require paired sera to demonstrate rises in antibody titer. Culture of M. pneumoniae is time-consuming, requires up to 4 weeks for results, and is relatively insensitive.
These drawbacks of serology and cultivation emphasize the need to develop rapid tests for the diagnosis of M. pneumoniae in order to allow the initiation of antibiotic treatment at the onset of infection. For this purpose, antigen detection (9) and molecular hybridization with DNA probes (6, 11, 14) have been proposed; despite good specificities, these tests do not allow the detection of low levels of M.
pneumoniae. More recently, C. Bernet et al. (1) and J. Skov Jensen et al. (13) reported the use of polymerase chain reaction (PCR) for in vitro amplification of M. pneumoniae DNA. Using different sets of primers, these authors showed that PCR allowed the specific detection of M. pneumoniae DNA sequences, while DNA from other Mycoplasma species gave negative results. The sensitivity of the PCR assay was evaluated with simulated clinical samples (artificially seeded throat swabs or bronchoalveolar lavages). In these experiments, the detection level of M. pneumoniae was estimated in a range of 10 to 40 color-changing units (CCU). The specificity, the exquisite sensitivity, and the relative rapidity of PCR make this technique promising for the rapid * Corresponding author. diagnosis of M. pneumoniae infections. However, the use of PCR as a diagnostic method still needs to be validated with clinical samples, and no report of such data has been published to date.
In this prospective study, we have evaluated the use of PCR to detect M. pneumoniae in clinical samples (nasopharyngeal aspirations or bronchoalveolar lavages) obtained from 100 children, 1 month to 16 years old. The results are compared with cultivation and serological data for M. pneumoniae.
MATERIALS AND METHODS
Patients. Clinical specimens were obtained from 100 children admitted to Trousseau Hospital between February and June 1991. Informed consent was obtained from the parents. The mean age was 7 + 0.9 years (range, 1 month to 16 years). Children were divided into four groups according to their clinical status: group I (n = 28) included children with acute respiratory diseases (pneumonia, bronchitis, and attacks of asthma), group II (n = 9) included children with cystic fibrosis, group III (n = 40) included children with chronic pulmonary disease but without acute symptomatology (obstructive bronchopneumopathy and asthma and one patient with lipidic interstitial pneumopathy), and group IV (n = 23) included immunocompromised children. Clinical samples obtained for M. pneumoniae cultivation and DNA amplification were nasopharyngeal aspirations (NPA) (n = 83), bronchoalveolar lavages (BAL) (n = 30), or pleural fluid (n = 1). In this study, BAL were done for indications other than M. pneumoniae detection. Each time it was possible, paired sera were obtained for M. pneumoniae antibody detection.
Acute-phase and convalescent-phase sera were taken 1 to 7 and 8 to 30 days, respectively, after the onset of disease.
DNA extraction and amplification. DNA was extracted from clinical samples by the method described by Boom et al. (2) . Briefly, 100 ,ul of a BAL or an NPA sample was incubated for 10 min at room temperature with 40 p,l of silica particles suspended in 900 pl of lysis buffer (1 M guanidine isothiocyanate, 0.1 M Tris HCl [pH 6.4], 0.036 M EDTA, 1% Triton X-100). After being centrifuged (1 min, 12 ,000 x g), the pellet was washed twice with 1 M guanidine isothiocyanate-0.1 M Tris HCl (pH 6.4), twice with ethanol (70%), and once with acetone. The dried pellet was then resuspended in 100 ,ul of distilled water, heated for 10 min at 56°C, and centrifuged (2 min, 12,000 x g), and the DNA-containing supernatant was stored at 4°C.
Prior to M. pneumoniae amplification, each DNA sample was tested for its ability to be amplified with the 1-globinspecific primers KM38 and KM39 (12) One color-changing unit was estimated to be equivalent to 10 to 100 organisms (1).
Serology. Determination of M. pneumoniae-specific antibody was performed by using a commercial microparticle agglutination assay (Serodia Myco II; Fujirebio, Inc., Tokyo, Japan) according to the manufacturer's recommendations. An antibody titer of <40 was regarded as negative. A threefold rise in titers of paired sera and titers of >160 were considered significant.
RESULTS
In order to appreciate the sensitivity of our PCR assay, we amplified DNA extracted from serial 10-fold dilutions of M. pneumoniae FH at a known concentration. One colorchanging unit of M. pneumoniae per 0.1 ml of PCR sample (estimated to be equivalent to 10 to 100 organisms) was consistently detected, and 0.1 CCU was detected in only 25% of the reactions. The detection limit of the PCR assay was thus estimated to range from 10 to 100 CCU per ml of sample (i.e., 102 to 103 organisms). In addition, a reproducible decrease in hybridization signal intensity was obtained for the dilutions corresponding to 100, 10, and 1 CCU. In further PCR experiments, these standard dilutions were systematically included, allowing semiquantitation of M. pneumoniae particles in clinical samples (Fig. 1) . Amplification of human DNA and DNA from M. orale T519, M. salivarium A889, and M. genitalium G37c gave negative results, confirming the specificity of the primer set MP5-1-MP5-2 described by C. Bernet et al. (1) . niques of DNA preparation from clinical samples (BAL and NPA): one included lysis with proteinase K followed by conventional phenol-chloroform extraction and ethanol precipitation, one was rapid lysis with proteinase K followed by heat inactivation, and the third was the guanidine isothiocyanate technique described in Materials and Methods. When the quality of the DNA used for amplification was tested with ,-globin primers, the first two methods gave poor results (less than 10% positive amplification), while the third method allowed the amplification of about 80% of the samples. In addition, similar results were obtained when control BAL and NPA were artificially seeded with 100 CCU of M. pneumoniae and amplified with the MPS-1-MPS-2 primers. All samples negative for ,B-globin amplification were also negative for M. pneumoniae amplification, indicating that the inhibition of amplification was most likely due to the presence of trace contaminants. In contrast, M. pneumoniae DNA was detected by PCR in all samples positive for ,-globin amplification. In these cases, the hybridization signal intensity was equivalent to that of the corresponding control standard (100 CCU of the FH strain) diluted in buffer. Thus, dilution of M. pneumoniae in samples positive for 3-globin amplification seems to have little influence on PCR sensitivity.
During the study conducted between February and June 1991, 83 NPA, 30 BAL, and 1 sample of pleural fluid were collected from 100 children admitted to Trousseau Hospital. In order to detect possible inhibition of the PCR, DNA extracted from these samples was tested with the KM38 and KM39 P-globin-specific primers. A characteristic 3-globinamplified product was obtained for 75% of the samples, and 65 children had at least one P-globin-positive sample. The results of MP-PCR were considered only when DNA was found to be amplified with P-globin-specific primers. Thus, in order to eliminate possible false-negative results, only samples positive for ,-globin and negative for MP-PCR were considered MP-PCR negative, while samples negative for , 3- Detailed results for the 20 children (7 girls and 13 boys) with positive MP-PCR results are shown in Table 2 . In 16 cases, PCR detection ofM. pneumoniae was associated with acute respiratory symptomatology: acute pneumonia (n = 10), asthma attacks (n = 2), cystic fibrosis with pulmonary exacerbation (n = 3), and histiocytosis X with acute bronchitis (n = 1). No pathogenic bacterial agent other than M. pneumoniae could be detected, except with patient 3, for whom Haemophilus influenzae was isolated from sputum. M. pneumoniae DNA was detected in 13 NPA, 7 BAL, and 1 sample of pleural fluid and in both the NPA and BAL specimens from one child. For each specimen, the amount of M. pneumoniae DNA in the PCR was estimated in a semiquantitative way by comparison of hybridization signals with those obtained for 100, 10, and 1 CCU ofM. pneumoniae FH (Fig. 1) . PCR values were then converted into the equivalent color-changing units per milliliter of clinical sample. M. pneumoniae PCR quantitation results ranged from low values (<102 CCU/ml) to high values (.104 CCU/ml). Low values were found in all asymptomatic (group III) patients and cystic fibrosis (group II) patients and in the two patients with acute asthma. In contrast, the amount of M. pneumoniae in clinical samples was higher for 8 out of 10 patients with acute pneumonia (groups I and IV). The single culturepositive sample (from patient 4) was quantified by PCR as >10' CCU/ml. In addition, the low level found for patient 5 could possibly be due to high dilution of the microorganism in pleural fluid. For patient 20, the amount of M. pneumoniae in the BAL specimen was found to be 10-fold greater than that in the NPA specimen. With regard to M. pneumoniae serology, three points deserve to be noted. (i) In 4 cases, seroconversion or antibody titers of 2160 in convalescent-phase serum were concordant with PCR results.
(ii) In 10 cases, antibodies were not detected in paired sera or in convalescent-phase serum and seemed inconsistent with PCR results. However, this lack of antibody response was observed particularly for all immunocompromised, group IV patients (n = 4) and infants less than 12 months old (patients 4, 5, and 10), one of whom was positive for M. pneumoniae cultivation. (iii) In five cases, antibodies were not detected in acute-phase sera obtained 2 to 7 days after the onset of disease. Unfortunately, convalescent-phase sera were not available, and one cannot exclude a further increase in antibody titers.
DISCUSSION
The aim of this study was to evaluate the use of the PCR technique for the diagnosis of M. pneumoniae infections in children. One of the major drawbacks we encountered was obtaining DNA pure enough to be amplified. Inhibition of amplification was more likely due to the presence of trace contaminants. Such inhibition in other systems has been previously described as a source of false-negative PCR results (4) . Therefore, the diagnosis of infectious agents by using PCR imperatively requires adaptation of the DNA preparation to the nature of the clinical samples, and the quality of the DNA to be amplified must be tested before PCR results are interpreted. In this study, even if the guanidine isothiocyanate DNA extraction method were the most reliable, only 75% of the clinical samples could be amplified, and efforts to improve DNA quality are currently under way.
When applied to clinical samples, PCR detected M. pneumoniae far more frequently than culture. Limited data comparing PCR and culture methods are available. However, PCR was shown to be more sensitive and reproducible than culture for detecting M. pneumoniae in throat swabs from experimentally infected hamsters (1) . Taking into account the semiquantitative PCR results, the culture-positive sample was one of those containing the largest amounts of M. pneumoniae (>104 CCU/ml). One can hypothesize that culture positivity may be partly related to the presence of a large number of organisms in the sample with the culture system we used.
Among PCR-positive patients, one experienced seroconversion and three already had high antibody titers when the sera were obtained. By the microparticle agglutination assay, antibody titers of 2160 have been shown to be diagnostically indicative of an acute M. pneumoniae infection (5) (11) , positive probe test results were found for control patients, but the values were lower than those for patients with confirmed M. pneumoniae infections. Thus, raising the PCR positivity limit to values greater than 102 CCU/ml as indicative of acute symptomatic infection deserves serious consideration. However, PCR detection of M. pneumoniae in asymptomatic patients may be of importance, as it could lead to a better understanding of the epidemiology and pathogenicity of M. pneumoniae. Analysis of sequential samples will be rxeded to estimate for how long M. pneumoniae can be detected by PCR after the onset of infection. In our experience, PCR did not detect M. pneumoniae in a sample obtained 2 months after the onset of infection in patient 20, who had received erythromycin and had experienced clinical improvement in the meantime.
Finally, with respect to the possibly false-positive PCR results, the clinical outcomes of the patients could be critical to assessing the reality of M. pneumoniae infection. Among the 20 PCR-positive patients, 5 group I and 3 group IV patients with acute pneumonia had received specific therapy with erythromycin. In four cases, culture and serology were negative and M. pneumoniae was detected only by PCR. The treatment was effective, and all patients had complete clinical and radiological recoveries within their 2-month follow-up visits. In these cases, the clinical outcome was compatible with M. pneumoniae infection. Patients with mild symptomatology and asymptomatic patients were not treated. Cystic fibrosis patients received broad-spectrumantibiotic therapy. For these patients, it seems difficult to assess the role of M. pneumoniae in the course of the disease.
The poor sensitivity of culture and the possibility of impaired serological responses make the PCR assay promising for the diagnosis of M. pneumoniae infections. In addition, PCR is fast enough to allow for the early application of therapy with a specific antibiotic. However, standardization of the PCR assay, including technical improvement of the DNA extraction step and PCR quantitation as well as interpretation of positive results, will be needed before this test can be proposed on a routine basis. For this purpose, the use of a nonisotopically labeled probe would make the test much more practical. Easier detection of M. pneumoniae by PCR may lead to an emphasis on its role in pulmonary or extrapulmonary infections. However, additional studies are still required in order to validate the PCR assay with a large number of clinical samples.
